HOME >> BIOLOGY >> NEWS
Studies at cancer conference show new therapies changing outlook for blood cancer patients

Orlando, FL and North Hollywood, CA, December 8, 2006 -- The International Myeloma Foundation (IMF) conducting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians today noted that multiple studies presented at the 2006 Annual Meeting of the American Society of Hematology (ASH) illustrate the breadth of the gains being made in the treatment of multiple myeloma and related blood cancers. The findings show that new treatment regimens that began with THALOMID and extend to both VELCADE and the newest oral treatment REVLIMID are helping a growing range of myeloma patients when used alone, sequentially and in various combinations. Collectively, these studies represent a significant increase in knowledge of how myeloma responds to treatment, which is already becoming applicable to other cancers.

The patient groups studied cover the full range, from relapsed patients to the newly diagnosed, young to old, and include patients with an otherwise poor prognosis due to chromosomal abnormalities. In some cases the data being presented at the conference significantly advances previous studies to show long-term response in newly diagnosed patients. In one of the most significant studies, researchers from the Mayo Clinic report 67% of patients using REVLIMID (plus the steroid dexamethasone) as primary therapy, achieved a response categorized as complete or very good, with a low rate of disease progression continuing even after two years.

"The many studies being presented at ASH not only confirm the good news we have been experiencing firsthand in our work with myeloma patients, but show that working with new classes of drugs is actually teaching us about treating cancer," said Brian G. M. Durie, M.D., myeloma specialist and chairman and co-founder of the International Myeloma Foundation. "We are learning to attack not just the cancer cell, but the environment in which it lives. We know that dr
'"/>


8-Dec-2006


Page: 1 2 3

Related biology news :

1. Studies to find better ways to preserve human eggs, ovarian tissue under way
2. Studies assess effectiveness of serotonin and nerve stimulants on irritable bowel syndromes
3. The Institute of Ecosystem Studies recognized by the Wildlife Society
4. The Institute of Ecosystem Studies to host an international conference on ecology and urban design
5. Hot flashes -- Studies explore the role of genes, obesity and alcohol
6. Studies force new view on biology of flavonoids
7. Studies of population genetics, evolution are an exercise in bad taste
8. Studies identify DNA regions linked to nicotine dependence
9. Studies find general mechanism of cellular aging
10. Institute of Ecosystem Studies director and scientist honored by the Botanical Society of America
11. Studies show that rockfish thrive with offshore platforms as their home base

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... Switzerland (PRWEB) , ... June ... ... provider of enterprise software solutions for biopharmaceutical R&D, today announced that it ... company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... antibody development services, today announced that the company has received ISO9001:2015 certification ... pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation demonstrates ...
(Date:6/23/2020)... ... June 23, 2020 , ... Rigaku Corporation , ... event in a series of TOPIQ webinars, which will cover the Transferable Aspherical ... developed in response to social distancing measures that resulted in postponements and cancelations ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 08, 2020 , ... Bode ... significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES . ... , Bode-CARES provides a turnkey solution that includes a comprehensive ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering ... to 200 million stem cells. Depending on the patient's condition, treatment may be offered ... will die having some form of Alzheimers dementia, and the incidence continues to increase ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... the launch of a new clinical diagnostics immuno-oncology service, TissueInsight . ... (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and ...
(Date:6/28/2020)... ... June 26, 2020 , ... The Security Industry ... its strong opposition to the recently introduced bicameral Facial Recognition and Biometric ... most federal use of nearly all biometric and related image analytics technologies, incorrectly ...
Breaking Biology Technology:
Cached News: